Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Inclusion Criteria: Age≥18 years old; Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset; Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT; Tirofiban or placebo treatment can be initiated within 6h after IVT; mRS score before onset≤ 1; Intracranial hemorrhage is ruled out by CT head after IVT; Systolic blood pressure before enrollment≤ 160mmHg; Exclusion Criteria: Received or plan to undergo bridge therapy; Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area); Atrial fibrillation or suspected cardiac embolism; Accompanied by epileptic seizures; Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment; Active bleeding or tendency to bleed after receipt of intravenous thrombolysis; Digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year; Severe renal or liver insufficiency; ALT or AST>3 times of the upper limit of normal value or above; creatinine clearance rate<30 mL/min, creatinine>200μmol/L； Life expectancy less than 3 months; Pregnant or lactating women; Known allergy to tirofiban; Being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.; Patients who are unwilling to be followed up or likely to have poor treatment compliance; Other situations that the researcher deems unsuitable for inclusion in the study.